GlassScriptPhysician profile
Kaitlin Galata
NPI 1215217278
$6,040.33
in general payments reported to CMS, 2019-2025
23 companies · $2,596 in 2025
The $2,596 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $307 · 2023: $562 · 2024: $2,575 · 2025: $2,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,567 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,567.21 |
| Education | $165.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $854.24 | 2024-2025 | |
| Janssen Biotech, INC. | $672.09 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| Incyte Corporation | $533.75 | 2023-2025 | Opzelura |
| Genzyme Corporation | $515.89 | 2024-2025 | |
| Ucb, INC. | $496.97 | 2024-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $459.32 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $404.91 | 2023-2025 | |
| Journey Medical Corporation | $322.09 | 2022-2025 | |
| Pfizer INC. | $296.79 | 2022-2025 | |
| Leo Pharma INC. | $263.78 | 2023-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $218.43 | 2024-2025 | Dupixent |
| Dermavant Sciences, INC. | $187.90 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $153.64 | 2022-2025 | |
| Lilly USA, LLC | $142.47 | 2022-2025 | Ebglyss, Taltz |
| Amgen INC. | $132.71 | 2023-2025 | Otezla, Otezla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $75.13 | 2024-2025 | Zoryve |
| Mayne Pharma Commercial LLC | $69.55 | 2025 | |
| Verrica Pharmaceuticals INC. | $59.77 | 2024-2025 | Ycanth |
| Organon LLC | $46.10 | 2025 | Vtama |
| Nobelpharma America, LLC | $45.80 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.88 | 2024 | Cyltezo |
| Biofrontera INC. | $31.50 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Galderma Laboratories, L.P. | $25.62 | 2023 | Epsolay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Galata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.